All In Biotech

Drug Trial Radar · NCT00036270

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients

Last checked: Nov 19, 2026Latest source record: Oct 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 9,779 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,779

Actual

Start

Aug 2001

Primary completion

Oct 2008

Study completion Feb 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 9, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.

Conditions

  • Breast Neoplasms

Interventions

  • exemestane (Aromasin)Drug

    exemestane, orally, 25 mg, for 5 years

  • tamoxifen + exemestaneDrug

    tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 YearsTime frame: Baseline (Month 0) up to 2.75 years
  2. Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 YearsTime frame: Baseline (Month 0) up to 5 years

Locations

179 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Bessemer, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Flagstaff, Arizona

  • Pfizer Investigational Site

    Green Valley, Arizona

  • Pfizer Investigational Site

    Oro Valley, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Safford, Arizona

  • Pfizer Investigational Site

    Scottsdale, Arizona

  • Pfizer Investigational Site

    Sedona, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tuscon, Arizona

  • Pfizer Investigational Site

    North Little Rock, Arkansas

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Boulder, Colorado

  • Pfizer Investigational Site

    Colorado Springs, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Fort Collins, Colorado

  • Pfizer Investigational Site

    Lakewood, Colorado

  • Pfizer Investigational Site

    Lone Tree, Colorado

  • Pfizer Investigational Site

    Longmont, Colorado

  • Pfizer Investigational Site

    Pueblo, Colorado

  • Pfizer Investigational Site

    Thornton, Colorado

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Hudson, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Lauderhill, Florida

  • Pfizer Investigational Site

    Melbourne, Florida

  • Pfizer Investigational Site

    New Port Richey, Florida

  • Pfizer Investigational Site

    Ocala, Florida

  • Pfizer Investigational Site

    Orange Park, Florida

  • Pfizer Investigational Site

    Palatka, Florida

  • Pfizer Investigational Site

    Plantation, Florida

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.